Navigation Links
New Treatment For Obstructive Sleep Apnea Now Available In Canada
Date:11/19/2012

nt has been used effectively in the United States since 2008 and in clinical studies, Provent Therapy improved quality of sleep while it reduced apnea (breathing disruptions), daytime sleepiness and snoring. Importantly, Provent is easy to use, portable and discreet for use at home or when travelling."

CPAP is the primary treatment of OSA and is extremely effective if worn as directed. However, up to half of all patients are not compliant with CPAP therapy due to the cumbersome nature of the treatment. Provent Therapy was developed to help patients who cannot tolerate CPAP therapy and will benefit from the small, non-invasive and effective technology, which Provent Therapy provides.

In patients with OSA the airway collapses during sleep when the muscles that hold it open relax. People with this disorder stop breathing during sleep---in some cases hundreds of times each night---usually for periods of ten seconds or longer. OSA can lead to fatigue, early morning headaches, irritability, lack of concentration, and contributes to depression, learning and memory difficulties, and sexual dysfunction. Importantly, recent studies have shown that OSA is associated with high blood pressure, irregular heartbeat, heart attack, stroke and diabetes.

"As we look at global market opportunities for Provent Therapy, Canada fits directly into our corporate strategy, which is to target markets where three factors come together: high prevalence of OSA, acceptance of innovative therapies, and importantly, a need for new therapeutic options that address low patient compliance," stated Peter Wyles, President and Chief Executive Officer of Ventus Medical. "With ioSleep and their extensive experience in sleep disorder treatment and diagnosis, we are pleased to present Provent Therapy as a new treatment to manage this troubling condition."

About Provent® Sleep Apnea Therapy

Provent is a proprietary medical device used for the treatment of O
'/>"/>

SOURCE Ventus Medical
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Research and ... Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market ... For the purposes of this report, the human microbiome ... The human microbiome market is expected to be valued ... at a CAGR of 22.3% within the forecast period of ...
(Date:9/19/2014)... Sept. 19, 2014 UBM Medica US announces ... online community to help oncologists and other clinicians gain ... the use of targeted therapies and immunotherapies, discusses some ... treatment.  Every September, Blood Cancer ... raise awareness about blood cancers—helping to increase survival rates ...
(Date:9/19/2014)... -- Alere Inc. (NYSE: ALR ), a global ... in support of President Barack Obama,s Executive ... leader in rapid diagnostics for infectious disease, we commend ... the serious threat of antibiotic resistance. We look forward ... to promote the development of rapid point-of-care tests that, ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
... PLEASANTON, Calif., Oct. 28 Thoratec Corporation (Nasdaq: ... circulatory support therapies to save, support and restore failing ... quarter of 2010 increased 40 percent versus the third ... for both the third quarter and first nine months ...
... (NYSE: RMD ) today announced record revenue and ... the quarter ended September 30, 2010 was $282.0 million, a ... over the quarter ended September 30, 2009.  For the quarter ... and net income was $56.7 million, an increase of 26% ...
Cached Medicine Technology:Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 2ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 3ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 4ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 5ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010 6
(Date:9/21/2014)... United-Kingdom (PRWEB) September 22, 2014 PhUSE ... Sweeney and Dr. Lilliam Rosario as keynote speakers for ... Following keynotes from Dr. Ben Goldacre in 2013 ... Professor Lord Winston in 2011 , PhUSE again presents ... who are passionate about advancement of clinical information. , ...
(Date:9/21/2014)... September 21, 2014 Expert witness work ... the findings from its 2014 Expert Witness Fees & ... complex, the demand and compensation for qualified and credentialed ... the Survey’s 16-year history. , The nearly 600 ... for their expert work, an increase of 3.2% from ...
(Date:9/21/2014)... September 21, 2014 Over the past ... drugs to inundate the market, thereby cutting into revenue ... industry. According to data from Industry Canada, the loss ... industry $1.8 and $2.5 billion in 2010 and 2012, ... patent exclusivity, which has hampered revenue growth, many pharmaceutical ...
(Date:9/21/2014)... understand why cancer cells metastasize? Think of Sparta. , ... better prepared them for the demands of battle on ... same thing according to a new study revealing previously ... at the original tumor site, and those that travel ... unyielding ability to metastasize is the primary cause of ...
(Date:9/21/2014)... 21, 2014 Hundreds of Risperdal ... in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein ... proceeding’s next monthly meeting has been scheduled for ... , “Our Firm is representing a number of ... litigation. We are pleased with its continued progress,” ...
Breaking Medicine News(10 mins):Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 2Health News:PhUSE announces Final List of Industry Influencers as Keynote Speakers 3Health News:ExpertPages 2014 Survey Reports Expert Witness Hourly Fees Record All-Time Highs as Demand for Qualified Experts Continues to Grow 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4
... Demand for Dark Chocolate by Active, On-the-Go Consumers , , ... Fueled by demand for nutritious, yet delicious snacks, Abbott ... ZonePerfect (R) Dark Chocolate Nutrition Bars - Dark ... Creme. , , Made with real cacao, ZonePerfect ...
... YORK, June 2 , ... 1991 , PharmaPendium ( http://www.info.pharmapendium.com/ ... drug,information, has significantly expanded its coverage of US Food ... the FDA Classic,Collection. This collection contains all available historical ...
... for Focus, Performance and Recovery , , HUNTINGTON BEACH, ... high-performance sports water designed ... to give them an edge, in terms of focus, better ... , , "With AquaHydrate, we believe ...
... be used to perform several screens, researchers say , TUESDAY, ... stool can accurately screen for more types of cancer than ... DNA stool testing has been successfully used for early detection ... that the noninvasive screening is also good at finding other ...
... researchers have demonstrated that a noninvasive screening test can detect ... the colon -- including pancreas, stomach, biliary and esophageal cancers. ... being presented at Digestive Disease Week 2009 in Chicago, May ... for approximately one in four cancer deaths. While high cure ...
... 2 June 2009 -- PharmaPendium ( http://www.info.pharmapendium.com ), ... drug information, has significantly expanded its coverage of US ... launch of the FDA Classic Collection. This collection contains ... including those issued in 1991 all indexed and ...
Cached Medicine News:Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 2Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 3Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 2Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 4Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 3Health News:Elsevier's PharmaPendium introduces the FDA Classic Collection 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: